JP7729639B2 - ピロロキノリンキノントリリチウム塩九水和物化合物を含む医薬組成物、カプセル剤およびその製造方法 - Google Patents

ピロロキノリンキノントリリチウム塩九水和物化合物を含む医薬組成物、カプセル剤およびその製造方法

Info

Publication number
JP7729639B2
JP7729639B2 JP2023539383A JP2023539383A JP7729639B2 JP 7729639 B2 JP7729639 B2 JP 7729639B2 JP 2023539383 A JP2023539383 A JP 2023539383A JP 2023539383 A JP2023539383 A JP 2023539383A JP 7729639 B2 JP7729639 B2 JP 7729639B2
Authority
JP
Japan
Prior art keywords
compound
pyrroloquinoline quinone
trilithium salt
salt nonahydrate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023539383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500545A5 (cg-RX-API-DMAC10.html
JP2024500545A (ja
Inventor
チャン、ホアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Raising Pharmaceutical Co Ltd
Original Assignee
Shanghai Raising Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Raising Pharmaceutical Co Ltd filed Critical Shanghai Raising Pharmaceutical Co Ltd
Publication of JP2024500545A publication Critical patent/JP2024500545A/ja
Publication of JP2024500545A5 publication Critical patent/JP2024500545A5/ja
Application granted granted Critical
Publication of JP7729639B2 publication Critical patent/JP7729639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023539383A 2020-12-28 2021-12-15 ピロロキノリンキノントリリチウム塩九水和物化合物を含む医薬組成物、カプセル剤およびその製造方法 Active JP7729639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011573509.7 2020-12-28
CN202011573509.7A CN112274513B (zh) 2020-12-28 2020-12-28 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法
PCT/CN2021/138255 WO2022143168A1 (zh) 2020-12-28 2021-12-15 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Publications (3)

Publication Number Publication Date
JP2024500545A JP2024500545A (ja) 2024-01-09
JP2024500545A5 JP2024500545A5 (cg-RX-API-DMAC10.html) 2025-05-01
JP7729639B2 true JP7729639B2 (ja) 2025-08-26

Family

ID=74426482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539383A Active JP7729639B2 (ja) 2020-12-28 2021-12-15 ピロロキノリンキノントリリチウム塩九水和物化合物を含む医薬組成物、カプセル剤およびその製造方法

Country Status (5)

Country Link
US (1) US20240058323A1 (cg-RX-API-DMAC10.html)
EP (1) EP4268821A4 (cg-RX-API-DMAC10.html)
JP (1) JP7729639B2 (cg-RX-API-DMAC10.html)
CN (1) CN112274513B (cg-RX-API-DMAC10.html)
WO (1) WO2022143168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274513B (zh) * 2020-12-28 2021-03-26 上海日馨生物科技有限公司 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006025247A1 (ja) 2004-08-30 2006-03-09 Kaneka Corporation ミトコンドリア賦活剤
JP2011126812A (ja) 2009-12-17 2011-06-30 Mitsubishi Gas Chemical Co Inc ピロロキノリンキノンＬｉ塩の製造方法
JP2015187097A (ja) 2014-03-13 2015-10-29 大正製薬株式会社 固形製剤
JP2016522224A (ja) 2013-07-01 2016-07-28 シャンハイ リーシェン バイオテクノロジー カンパニー リミテッド ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63215628A (ja) * 1987-03-03 1988-09-08 Sogo Yatsukou Kk グリオキサラ−ゼｉ阻害剤
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
CN101851234A (zh) * 2009-04-03 2010-10-06 上海日馨生物科技有限公司 吡咯喹啉醌锂盐衍生物及其制备方法
JP6160621B2 (ja) * 2012-08-17 2017-07-12 三菱瓦斯化学株式会社 ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物
US9732079B2 (en) * 2013-04-26 2017-08-15 Mitsubishi Gas Chemical Company, Inc. Yellow reduced pyrroloquinoline quinone crystal and method of producing the same, and food, pharmaceutical, gel, composition and method of producing composition
CN112274513B (zh) * 2020-12-28 2021-03-26 上海日馨生物科技有限公司 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006025247A1 (ja) 2004-08-30 2006-03-09 Kaneka Corporation ミトコンドリア賦活剤
JP2011126812A (ja) 2009-12-17 2011-06-30 Mitsubishi Gas Chemical Co Inc ピロロキノリンキノンＬｉ塩の製造方法
JP2016522224A (ja) 2013-07-01 2016-07-28 シャンハイ リーシェン バイオテクノロジー カンパニー リミテッド ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用
JP2015187097A (ja) 2014-03-13 2015-10-29 大正製薬株式会社 固形製剤

Also Published As

Publication number Publication date
CN112274513B (zh) 2021-03-26
JP2024500545A (ja) 2024-01-09
US20240058323A1 (en) 2024-02-22
EP4268821A4 (en) 2024-12-11
CN112274513A (zh) 2021-01-29
EP4268821A1 (en) 2023-11-01
WO2022143168A1 (zh) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7216055B2 (ja) 医薬組成物
JP7471675B2 (ja) 多孔性シリカ粒子組成物
JP5278708B2 (ja) ナテグリニド含有親水性医薬製剤
JP5289975B2 (ja) マンニトール又は乳糖を含有する固形製剤
TWI788557B (zh) 穩定性優異的固態製劑
EP1027037A1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
TWI872459B (zh) 含藥物之立即釋放錠劑及形成該錠劑的方法
JP2018058911A (ja) 口腔内崩壊錠
JP7809780B2 (ja) 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
JP2024010032A (ja) ボルチオキセチン臭化水素酸塩を含む口腔内味マスキング用コーティング顆粒、固体分散体及び製剤
TWI794214B (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
JP2018515520A (ja) ボルチオキセチンピログルタミン酸塩
JP2023156269A (ja) テネリグリプチン含有医薬組成物
KR102333463B1 (ko) 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
JP7382737B2 (ja) イストラデフィリン製剤
CN113058038A (zh) 含有托格列净的固体制剂及其生产方法
EP4268821A1 (en) Pharmaceutical composition containing pyrroloquinoline quinone trilithium salt nonahydrate compound, capsule, and preparation method therefor
JP7650274B2 (ja) ゾニサミド口腔分散性錠剤
JPH09504800A (ja) クロドロネート製剤の製造方法
CN120022270A (zh) 一种吲哚布芬缓释制剂及其制备方法和应用
JP2012180280A (ja) 貯蔵安定性が改善された固形製剤
JP2001213890A (ja) トレハロース粒子
JP2021104974A (ja) フェブキソスタット製剤
JP3934150B1 (ja) 固形製剤および製剤組成物
CN121731233A (zh) 一种司来帕格药物组合物及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250124

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7729639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150